Blue Chip Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
VCM
N
Blue Chip Partners's REGN Position: Q1 2026 in Review
Blue Chip Partners increased its Regeneron Pharmaceuticals (REGN) stake by 8.9% in Q1 2026, buying an estimated $64.3K and bringing the position to 1,029 shares worth $795K. The position accounts for 0.06% of the portfolio, ranked #100.
Blue Chip Partners first reported a position in REGN in Q1 2025 and has held it in 5 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Blue Chip Partners held 1,029 shares of Regeneron Pharmaceuticals worth $795K as of Q1 2026.
- Blue Chip Partners bought 84 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $64.3K.
- Regeneron Pharmaceuticals made up 0.06% of Blue Chip Partners's portfolio in Q1 2026, its #100 holding.
- Blue Chip Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Blue Chip Partners's 13F filing for Q1 2026, filed 15 May 2026.